OOIR: Observatory of International Research

Papers

(The H4-Index of Melanoma Research is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Impact of COVID-19 on melanoma diagnosis	18
Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)	17
The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials	17
C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting	16
Ultraviolet A radiation exposure and melanoma: a review	16
Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases	15
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	12
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors	11
Hemophagocytic lymphohistiocytosis of a melanoma patient under BRAF/MEK-inhibitor therapy following anti-PD1 inhibitor treatment: a case report and review to the literature	11
Nivolumab for metastatic uveal melanoma: a multicenter, retrospective study	10
The role of osteopontin in the development and metastasis of melanoma	10
Epigenetic therapy to enhance therapeutic effects of PD-1 inhibition in therapy-resistant melanoma	10
Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors	10
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	10
Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma	10
Transcriptional analysis of metastatic uveal melanoma survival nominates NRP1 as a therapeutic target	10
Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis	10
Clinical and immune correlate results from a phase 1b study of the histone deacetylase inhibitor mocetinostat with ipilimumab and nivolumab in unresectable stage III/IV melanoma	10
Efficacy of radiotherapy combined with immune checkpoint inhibitors in patients with melanoma: a systemic review and meta-analysis	10